Thanks for the mention mate. That podcast was a great insight, not often do we get to hear from Joel outside of the ASX Announcements. Suggest everyone have a listen...... https://thewallstreetresource.com/webcasts/
The commercialisation part that you and Joel mentioned is as follows
Jeff> okay, how about partners or your partnering strategy?
Joel > We work with the best companies in the biotech space. So whether it be regulatory consultants, formulation partners, commercialization partners, trial sites, CROs, we're working with the best and the most well-renowned organizations globally. We've built up some really strong partnerships. We've got our formulation partnerships in place, our regulatory partnerships in place, and we're going to continue to build on that over time.We have had various discussions in the pharmaceutical space around the commercialization of these assets given the fact that we have derisked each of our six assets because we do have positive results across the board. So we're open to partnership opportunities, but we are gearing our products in our assets towards commercialization ourselves.
Jeff> Okay, so the go-to-market strategy may be yourself or maybe your partner depending on the drug?
Joel > Yes, depending on the drug. So we haven't pigeonholed ourselves to wanting to partner with anyone on any of our assets as yet. I think it's important for us to have the foundations and the structures in place internally for us to commercialize each of our drug products.But if the right opportunity comes along, as we continue to develop each of our assets and continue to have positive results, we would be open to looking at other opportunities as we develop and evolve over time.
